Azacitidine
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Explore 128 assets in Peripheral T-Cell Lymphoma, Not Otherwise Specified →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Second Affiliated Hospital of Soochow University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07598578CT.gov An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma. | — | Recruiting | — | — | — |
NCT07388563CT.gov Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma | — | Suspended | — | — | — |
NCT07389616CT.gov A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma | — | Recruiting | — | — | — |
NCT07372352CT.gov Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL | — | Recruiting | — | — | — |
NCT07018752CT.gov A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas | — | Recruiting | — | — | — |
NCT05958719CT.gov Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma | — | Recruiting | — | — | — |
NCT05675813CT.gov Genotype-guided Treatment in Newly Diagnosed PTCL | — | Recruiting | — | — | — |
NCT05678933CT.gov AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH | — | Enrolling By Invitation | — | — | — |
NCT05559008CT.gov A Umbrella Study in R/R PTCL Guided by Molecular Subtypes | — | Unknown | — | — | — |
NCT05495100CT.gov A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma | — | Unknown | — | — | — |
Show 7 more trialsShow fewer
NCT04803201CT.gov Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | — | Suspended | — | — | — |
NCT04447027CT.gov Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies | — | Completed | — | — | — |
NCT04480125CT.gov Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy | — | Unknown | — | — | — |
NCT05182957CT.gov Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma | — | Recruiting | — | — | — |
NCT04068597CT.gov Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | — | Recruiting | — | — | — |
NCT03542266CT.gov CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma | — | Completed | — | — | — |
NCT01129180CT.gov Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peripheral T-Cell Lymphoma, Not Otherwise Specified
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Azacitidine (this asset) | Second Affiliated Hospital of Soochow University | P3 | B · 62 |
| Prednisone | Tarapeutics Science Inc. | P4 | BBB |
| Pralatrexate | Peking University People's Hospital | P4 | BBB |
| Adriamycin | BeBetter Med Inc | P4 | BBB |
| Cyclophosphamide | Tarapeutics Science Inc. | P4 | BBB |
| (+)-Vincristine | BeBetter Med Inc | P4 | BBB |
| Rivoceranib | Ruijin Hospital | P4 | BBB |
| Romidepsin | University of Virginia | P3 | BBB |
| Tucidinostat | Ruijin Hospital | P4 | BB |
+42 more in the Peripheral T-Cell Lymphoma, Not Otherwise Specified cohort
Other indications for Azacitidine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 73 |
| Acute Erythroid Leukemia | — | P2 | BB · 71 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Azacitidine in Peripheral T-Cell Lymphoma, Not Otherwise Specified. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/azacitidine-peripheral-t-cell-lymphoma-not-otherwise-specified
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →